Author: Knight Therapeutics

Posted Date:

May 12, 2026

Knight to Present at the 2026 RBC Capital Markets Global Healthcare Conference in New York City

Knight Therapeutics

May 12, 2026
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Brazil

Knight Therapeutics

May 8, 2026
Knight Therapeutics Reports First Quarter 2026 Results

Knight Therapeutics

May 8, 2026
Knight Therapeutics Inc. announces voting results from the Annual General Meeting

Knight Therapeutics

May 6, 2026
Notice of Knight Therapeutics’ First Quarter 2026 Results Conference Call

Knight Therapeutics

April 30, 2026
Knight to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

Knight Therapeutics

April 15, 2026
Knight Therapeutics Inc. ranks on The Globe and Mail’s second annual Canada’s Top Growing Women-Led Companies and seventh annual Women Lead Here benchmark of executive gender diversity

Knight Therapeutics

March 27, 2026
Knight Amends Normal Course Issuer Bid

Knight Therapeutics

March 23, 2026
Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results

Knight Therapeutics

March 19, 2026
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico

Knight Therapeutics

March 17, 2026